Shigella Infections - Pipeline Insight, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 31, 2019--The “Shigella Infections - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Shigella Infections - Pipeline Insight, 2019 offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Shigella Infections development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the ReportThe report provides a snapshot of the pipeline development for the Shigella Infections The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Shigella Infections The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Shigella Infections The report also covers the dormant and discontinued pipeline projects related to Shigella Infections
Companies FeaturedAnacor Pharmaceuticals GlaxoSmithKline PLC Microbiotix Protein Potential Visterra GlycoVaxyn
1. Report Introduction
2. Shigella Infections Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Shigella Infections
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name : Company NameProduct Description Research and Development Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company NameProduct Description Research and Development Product Development Activities
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company NameProduct Description Research and Development Product Development Activities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/nvd8j9/shigella?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190131005642/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/31/2019 10:58 AM/DISC: 01/31/2019 10:58 AM